Administration of recombinant human FGF21 (rhFGF21) lowered plasma glucose and insulin levels, reduced hepatic and circulating triglycerides and cholesterol levels, and improved insulin sensitivity, energy expenditure, and obesity in a variety of insulin resistant animal models [5], [11], [12]. Here, INS is linked to obesity due to melanocortin 4 receptor deficiency.